PMC PharMerica Corporation

PharMerica Corporation Announces Fourth Quarter and Year End 2016 Earnings Call and Webcast

LOUISVILLE, Ky.--(BUSINESS WIRE)--

PharMerica Corporation (NYSE:PMC) announced today that it will provide an online webcast of its fourth quarter and year end 2016 earnings conference call on Friday, February 24, 2017. The Company’s results for the fourth quarter and year ended December 31, 2016 will be released before the open of the market on Friday, February 24, 2017.

The live broadcast of PharMerica’s conference call will begin at 10:00 a.m. Eastern Time on Friday, February 24, 2017. A 7-day online replay will be available beginning at 1:00 p.m. Eastern Time following the conclusion of the live broadcast. A link to these events can be found under the Investor Relations section of the Company’s website, www.pharmerica.com.

About PharMerica

PharMerica Corporation is a leading provider of pharmacy services. PharMerica serves the long-term care, hospital pharmacy management services, specialty home infusion and oncology pharmacy markets. PharMerica operates 99 institutional pharmacies, 19 specialty home infusion pharmacies and 4 specialty oncology pharmacies in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, assisted living facilities, hospitals, individuals receiving in-home care and patients with cancer.

EN
03/02/2017

Underlying

PMCPharMerica Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PharMerica Corporation

 PRESS RELEASE
Free
PMC PharMerica Corp...

KKR Completes Acquisition of PharMerica

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE:PMC) today announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor. As a result of the completion of the acquisition, PharMerica shareholders will receive an amount in cash equal to $29.25 per share of PharMerica common stock, without interest. In connection with the completion of the acquisition, shares of PharMerica’s common sto...

December 7, 2017 1 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

PharMerica Reports Third Quarter 2017 Results

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the third quarter ended September 30, 2017. Third Quarter 2017 Results The results for the third quarter of 2017 are set forth below: Key Comparisons of Third Quarters Ended September 30, 2017 and 2016: Revenues for the third quarter of 2017 were $595.1...

November 9, 2017 1 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

PharMerica Announces Approval of Merger by Stockholders

LOUISVILLE, Ky.--(BUSINESS WIRE)-- PharMerica Corporation (NYSE: PMC), announced that at its special meeting of stockholders held today, a majority of the outstanding shares of PharMerica common stock voted to approve the adoption of the previously disclosed definitive merger agreement pursuant to which a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. (Nasdaq: WBA) as a minority investor, will acquire PharMerica. The closing of the transaction remains subject to customary closing conditions. ...

November 9, 2017 1 EN
Free Trial
PMC PharMerica Corp...

PHARMERICA CORP. reduces its risk exposure and slightly improves to Ne...

The independent financial analyst theScreener just allocated a lower risk rating to PHARMERICA CORP. (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date October 27, 2017, the closing price was USD 29.10 and i...

PMC PHARMERICA CORPORATION
10/28/17 October 28, 2017 6 EN
 PRESS RELEASE
Free
PMC PharMerica Corp...

Onco360 Selected for VERZENIO® Limited Distribution Pharmacy Network

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Onco360, the nation’s largest independent Oncology Pharmacy, announced today that it has been selected to participate in the limited distribution network for Eli Lilly and Company’s new product, VERZENIOTM (Abemaciclib), a twice daily oral cyclin-dependent kinase (CDK) 4/6 inhibitor approved by the U.S. Food and Drug Administration (FDA). VERZENIO is used in combination with fulvestrant to treat women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanc...

October 16, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch